Protocol Ledger

NCT03703466 · Phase II · COMPLETED

A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer

Interventional Phase II clinical trial protocol NCT03703466 sponsored by Eli Lilly and Company in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-11-28 Enrollment: 72 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03703466
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)72 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03703466
Protocol FieldVerified Registry Value
NCT IdentifierNCT03703466
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment72 participants (ACTUAL)
Registered Start Date2018-11-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03703466
Hospital Research SiteLocationSite Profile
Peter MacCallum Cancer CentreMelbourne, AustraliaOpen Hospital Dossier ->
Hospital Universitari Vall d'HebronBarcelona, SpainOpen Hospital Dossier ->
Hospital Clinico San CarlosMadrid, SpainOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI